ClinicalTrials.gg
CompletedNCT01217112Updated Oct 18, 2022Results posted

GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes

A Phase 2 interventional study of GWP42003 and GWP42003 in Dyslipidemias and Diabetes Mellitus, Type 2, sponsored by Jazz Pharmaceuticals. Completed at 5 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies in Dyslipidemias with a site in United Kingdom — 6 open to participants now, 9 under way, 3 of them phase 3. Dyslipidemias · United Kingdom.

Enrollment
35th of 48
62 · median 342
Started
2010
with 1 other
Phase 2
4 of 55
none open now
Registered
23rd of 55
by date

Among the 55 studies in Dyslipidemias with a site in United Kingdom, this one is the 35th largest by enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2010, is one of 4 in phase 2, and was the 23rd registered.

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

6 of the 55 studies in Dyslipidemias with a site in United Kingdom are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Dyslipidemias with a site in United Kingdom, or all of them as a file.
02

Study summary

This 15-19 week study is being conducted by GW Pharma Ltd as a pilot study in order to determine the efficacy and safety of two cannabinoids: GWP42004 and GWP42003 alone, or in combination in patients with Type 2 diabetes. This is the first study to determine whether the study medications have a positive benefit for subjects on their cholesterol levels, body weight, liver fat content and other metabolic parameters compared with a placebo medication.

Read the detailed description

In this study there was a 1-5 week baseline period followed by a 13 week treatment period, and a one week follow-up. Eligible subjects entered the study at a screening visit (Visit 1) before returning for randomisation (Visit 2, Day 1). At the discretion of the investigator (based on individual subjects), Visit 1 could be split into two separate visits (Visits 1A and B) to allow a 21-day washout period of prohibited medications prior to blood sampling for eligibility. Further outpatient study visits (for assessment purposes) took place at the study site at the end of Week 4 of treatment (Visit 3, Day 29), and at the overall end of treatment at Week 13 (Visit 5, Day 92). A telephone assessment was also performed at Day 57 (Visit 4) and at Week 14 (Visit 6, Day 99) for safety follow-up purposes.

During the 13 week randomised treatment phase, subjects received blinded, oral doses of their allocated randomised treatment twice daily. Treatment was self-administered on an outpatient basis, once in the morning and once in the evening for 13 weeks. Subjects were instructed to time study medication to 30 minutes before breakfast and evening meals.

Physical and metabolic parameters were assessed before, during and after treatment to evaluate clinical response. Diabetic and dyslipidaemic medication usage (where applicable), and appetite 0-10 NRS data were collected daily during the treatment period, using the study diary.

03

Conditions studied

  • Dyslipidemias
  • Diabetes Mellitus, Type 2

Keywords

  • Dyslipidemias
  • Diabetes
  • Liver Fat
  • Body Fat
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically diagnosed with Type 2 diabetes, with residual islet cell function;
  • Diet controlled or receiving oral anti-diabetic treatment (metformin or other biguanides and/or sulphonyl ureas) who have received a stable dose for at least 3 months prior to enrollment;
  • High Density Lipoprotein cholesterol ≤ 1.3mmol/L (females), ≤ 1.2mmol/L (males);
  • Glycosylated levels of ≤ 10%;
  • Triglycerides ≤ 10mmol/L;
  • Willing to maintain a stable dose of oral anti-diabetic and/or lipid-lowering agents/medications that may have an effect on plasma/serum glucose, insulin or lipid parameters for the duration of the study, where applicable;
  • No changes in diet or exercise for four weeks prior to and subject agrees to keep stable for the duration of the study (in the opinion of the investigator);

Exclusion criteria

Exclusion Criteria:

  • Subject is taking insulin (i.e. they are insulin-dependent);
  • Taking the following categories of medicines: fibrates, Thiazolidinediones, therapeutic Omega-3 fatty acids, alpha-glucosidase inhibitors and unwilling abstain for the duration of the study;
  • Currently using or has used recreational cannabis, medicinal cannabis, cannabinoid medications (including Sativex®), or synthetic cannabinoid based medications within 30 days prior to study entry and unwilling to abstain for the duration for the study;
  • Any known or suspected history of:

    • alcohol or substance abuse
    • epilepsy or recurrent seizures;
  • Any known or suspected history of depression sufficient to require treatment with antidepressants or disrupt ordinary life at the discretion of the investigator);
  • Subject who has significant history of anxiety, suicidal ideation or self-harm;
  • cardiac, renal or hepatic impairment in the opinion of the investigator;
  • Genetic dyslipidaemic condition in the opinion of the investigator;
  • Currently taking a lipid lowering agent and a stable dose has not been maintained for at least four weeks randomisation (Visit 2);
  • Female subject, who is pregnant, lactating or planning pregnancy during the course of the study and for three months from date of last dose;
  • Female subjects of child bearing potential unless willing to use two forms of , one of which must be barrier contraception (e.g. female condom or occlusive cap (diaphragm or cervical vault/caps) with spermicide) during the study and for three months thereafter;
  • Male subjects whose partner is of child bearing potential, unless willing to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g. female condom or occlusive cap (diaphragm or cervical vault/caps) with spermicide) during the study and for three months thereafter;
  • Body weight > 150kg;
  • Travel outside the country of residence planned during the study;
  • Currently receiving a prohibited medication and unwilling to stop at the screening visit and for the duration of the study;
  • Received an unapproved Medicinal Product (IMP) within the 30 days before the screening visit;
  • In the opinion of the investigator, is not considered to be suitable for the study;
  • Any known or suspected to cannabinoids or any of the of the IMP(s);
  • Any other significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, may influence the result of the study, or the subject's ability to participate in the study;
  • Has a postural drop of ≥ 20 mmHg in systolic blood pressure at Visit 1;
  • Any abnormalities identified during the physical exam at Visit 1 that in the opinion of the investigator, would prevent the subject from safe participation in the study;
  • Unwilling to abstain from donation of blood during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Active comparator
    GWP42004 and placebo

    Contains GWP42004 5 mg and placebo (excipients only)

    Drug: GWP42004 · Drug: Placebo

  • Active comparator
    1:1 GWP42003 : GWP42004

    Contains 5 mg each of GWP42003 and GWP42004

    Drug: GWP42003 · Drug: GWP42004

  • Active comparator
    20:1 GWP42003 : GWP42004

    Contains 100 mg GWP42003 and 5 mg GWP42004

    Drug: GWP42003 · Drug: GWP42004

  • Placebo comparator
    Placebo

    Contains excipients only

    Drug: Placebo

  • Active comparator
    GWP42003 and placebo

    Contains 100 mg GWP42003 and placebo (excipients only)

    Drug: GWP42003 · Drug: Placebo

Interventions

  • 100 mg capsules, PO, BD, 91 days

    Also known as: Cannabidiol, CBD

  • 5 mg capsules, PO, BD, 91 days

    Also known as: Cannabidiol, CBD

  • 5 mg capsules, PO, BD, 91 days

    Also known as: delta-9-tetrahydrocannabivarin, THCV

  • DrugPlacebo

    0 mg capsules, QDS, PO, 91 days

06

What researchers measure

Primary outcomes

  1. The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum High Density Lipoprotein cholesterol. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

Secondary outcomes

  1. The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of High Density Lipoprotein cholesterol by ultracentrifugation. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  2. The Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum total cholesterol. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  3. The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum total cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  4. The Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Low Density Lipoprotein cholesterol. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  5. The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of Low Density Lipoprotein cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  6. The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment

    An increase from baseline (i.e. a positive value) to the end of treatment in the High Density Lipoprotein : Low Density Lipoprotein cholesterol ratio indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  7. The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

    An increase from baseline (i.e. a positive value) to the end of treatment in the High Density Lipoprotein : Low Density Lipoprotein cholesterol ratio indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  8. The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of Very Low Density Lipoprotein cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  9. The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum triglyceride concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  10. The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of triglyceride concentrations by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  11. The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Apolipoprotein A. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  12. The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Apolipoprotein B. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  13. The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment

    A decrease from baseline to the end of treatment (i.e. a negative value) in the Apolipoprotein B : Apolipoprotein A ratio indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  14. The Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Non-Esterified Fatty Acid concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  15. The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fasting glucose concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  16. The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fructosamine concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  17. The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of glycated haemoglobin concentrations. At both time points, values were calculated as a percentage of total haemoglobin. A decrease from baseline to the end of treatment in base per cent values, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  18. The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])

    A two-hour OGTT was performed to investigate the rate of glucose metabolism or clearance from the blood with treatment. Blood samples were taken at -15 and 0 minutes prior to a glucose drink and at 30, 60, 90, 120 and 180 minutes post drink. The OGTT measured the change from baseline in serum glucose levels at two hours (120 minutes) compared to 0 minutes. The extent of the elevation in blood glucose levels following a glucose drink were compared between baseline and the end of treatment. A reduction in the elevation of serum glucose levels at the end of treatment (i.e. a negative value) indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  19. The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)

    At baseline and the end of treatment, blood samples were taken at -15 and 0 minutes prior to a glucose drink and at 30, 60, 90, 120 and 180 minutes post drink. The OGTT measured the change from baseline in serum insulin levels at two hours (120 minutes) compared to 0 minutes. The extent of the elevation in blood glucose levels following a glucose drink were compared between baseline and the end of treatment. An increase in the elevation of serum insulin levels from baseline to the end of treatment (i.e. a positive value) indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  20. The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fasting insulin concentrations. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  21. The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment

    At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of C-peptide concentrations. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  22. The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment

    Changes from baseline to the end of treatment in mean insulin resistance were calculated by HOMA2-IR. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin resistance, which is the reciprocal of insulin sensitivity (%S)(100/%S) as a percentage of a normal reference population (normal young adults). A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  23. The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment

    Changes from baseline to the end of treatment in mean insulin sensitivity were calculated by HOMA2. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). An increase from baseline to the end of treatment, a positive value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  24. The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment

    Changes from baseline to the end of treatment in mean insulin B Cell Function were calculated by HOMA2. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate beta cell function (%B) as a percentage of a normal reference population (normal young adults). An increase from baseline to the end of treatment, a positive value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  25. The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment

    Body Mass Index was calculated at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  26. The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment

    Subject's waist-to-hip ratios were calculated at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  27. The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment

    Subject's body weights were measured at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  28. The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment

    Subjects' waist measurements were taken at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  29. The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment

    Subjects' hip measurements were taken at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  30. The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment

    Visceral Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  31. The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment

    Subcutaneous Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  32. The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment

    Total Abdominal Fat was measured by magnetic resonance imaging, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  33. The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

    Internal Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  34. The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

    Subcutaneous Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  35. The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

    Total Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  36. The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment

    Total Internal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  37. The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment

    Total Subcutaneous Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  38. The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment

    Total Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  39. The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment

    Abdominal Adiposity was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  40. The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment

    Percentage liver fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment in base per cent values, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  41. The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment

    Subjects scored their appetite daily using an appetite 0-10 numerical rating scale score where 0 = no appetite (don't feel hungry) and 10 = maximum appetite (completely hungry all the time). The mean change from baseline to the end of treatment in scores were calculated. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

    Time frame: Baseline (Day 1) and End of treatment (Day 92)

  42. Adverse Events as a Measure of Patient Safety

    The incidence of treatment-emergent adverse events was recorded for the study duration, and the number of patients who experienced an adverse event is presented.

    Time frame: Day 1 - Day 92

  43. The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment

    The BDI-II is a 21 question, multiple choice, self-reported inventory, and is one of the most widely used instruments for measuring the severity of depression. The 21 questions or items each had four possible responses. Each response was assigned a score ranging from zero to three, indicating the severity of the symptom, with a total possible score ranging from zero to 63. A score between zero and 13 indicates 'minimal depression'. A score between 14 and 19 indicates 'mild depression'. A score between 20 and 28 indicates 'moderate depression', and a score between 29 and 63 indicates 'severe depression'. As such, an increase from baseline to the end of treatment, a positive value, indicates a deterioration.

    Time frame: Baseline (Day 1) and the End of Treatment (Day 92)

07

Results

Posted Jan 20, 2014

Participant flow

Participant flow — Overall Study
Milestone1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
Started1112131214
Completed1110121013
Not completed02121
Withdrew: Adverse event02020
Withdrew: Withdrawal by subject00100
Withdrew: Physician decision00001

Outcome measures

PrimaryThe Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum High Density Lipoprotein cholesterol. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum High Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment0.00 ± 0.090.04 ± 0.07-0.04 ± 0.140.00 ± 0.140.02 ± 0.09
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.766 · Mean difference (final values): -0.01 · 90% CI -0.09 to 0.06
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.424 · Mean difference (final values): 0.03 · 90% CI -0.04 to 0.11
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.412 · Mean difference (final values): -0.03 · 90% CI -0.10 to 0.04
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.668 · Mean difference (final values): 0.02 · 90% CI -0.05 to 0.09
SecondaryThe Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of High Density Lipoprotein cholesterol by ultracentrifugation. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean High Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment-0.04 ± 0.12-0.06 ± 0.08-0.11 ± 0.08-0.01 ± 0.16-0.02 ± 0.11
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.978 · Mean difference (final values): 0.00 · 90% CI -0.08 to 0.08
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.864 · Mean difference (final values): -0.01 · 90% CI -0.08 to 0.07
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.537 · Mean difference (final values): -0.03 · 90% CI -0.12 to 0.05
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.260 · Mean difference (final values): 0.05 · 90% CI -0.02 to 0.13
SecondaryThe Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum total cholesterol. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum Total Cholesterol Concentration After 91 Days (13 Weeks) of Treatment-0.53 ± 0.78-0.27 ± 0.32-0.22 ± 0.50-0.13 ± 0.44-0.09 ± 0.39
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.088 · Mean difference (final values): -0.31 · 90% CI -0.61 to -0.01
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.583 · Mean difference (final values): 0.10 · 90% CI -0.20 to 0.39
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.388 · Mean difference (final values): 0.15 · 90% CI -0.14 to 0.43
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.580 · Mean difference (final values): 0.09 · 90% CI -0.19 to 0.38
SecondaryThe Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum total cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Total Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment-0.12 ± 0.83-0.23 ± 0.28-0.11 ± 0.52-0.11 ± 0.45-0.16 ± 0.33
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.829 · Mean difference (final values): 0.04 · 90% CI -0.29 to 0.37
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.575 · Mean difference (final values): 0.11 · 90% CI -0.22 to 0.44
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.356 · Mean difference (final values): 0.19 · 90% CI -0.15 to 0.53
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.472 · Mean difference (final values): 0.14 · 90% CI -0.18 to 0.45
SecondaryThe Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Low Density Lipoprotein cholesterol. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum Low Density Lipoprotein Cholesterol Concentration After 91 Days (13 Weeks) of Treatment-0.29 ± 0.62-0.13 ± 0.36-0.11 ± 0.40-0.02 ± 0.500.07 ± 0.33
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.115 · Mean difference (final values): -0.29 · 90% CI -0.59 to 0.01
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.782 · Mean difference (final values): 0.05 · 90% CI -0.25 to 0.35
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.902 · Mean difference (final values): 0.02 · 90% CI -0.27 to 0.31
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.993 · Mean difference (final values): 0.00 · 90% CI -0.28 to 0.28
SecondaryThe Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of Low Density Lipoprotein cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment-0.03 ± 0.49-0.16 ± 0.26-0.08 ± 0.43-0.08 ± 0.41-0.06 ± 0.19
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.956 · Mean difference (final values): 0.01 · 90% CI -0.23 to 0.25
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.705 · Mean difference (final values): 0.05 · 90% CI -0.19 to 0.30
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.466 · Mean difference (final values): 0.11 · 90% CI -0.14 to 0.36
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.876 · Mean difference (final values): 0.02 · 90% CI -0.21 to 0.25
SecondaryThe Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment

An increase from baseline (i.e. a positive value) to the end of treatment in the High Density Lipoprotein : Low Density Lipoprotein cholesterol ratio indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · ratio
The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment
ratio1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio After 91 Days (13 Weeks) of Treatment0.03 ± 0.110.04 ± 0.05-0.02 ± 0.080.02 ± 0.090.01 ± 0.06
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.408 · Mean difference (final values): 0.03 · 90% CI -0.03 to 0.09
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.714 · Mean difference (final values): 0.01 · 90% CI -0.04 to 0.07
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.267 · Mean difference (final values): -0.04 · 90% CI -0.09 to 0.02
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.484 · Mean difference (final values): 0.02 · 90% CI -0.03 to 0.08
SecondaryThe Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

An increase from baseline (i.e. a positive value) to the end of treatment in the High Density Lipoprotein : Low Density Lipoprotein cholesterol ratio indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · ratio
The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
ratio1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean High Density Lipoprotein : Low Density Lipoprotein Cholesterol Ratio by Ultracentrifugation After 91 Days (13 Weeks) of Treatment-0.01 ± 0.110.00 ± 0.05-0.02 ± 0.080.03 ± 0.120.01 ± 0.06
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.560 · Mean difference (final values): -0.02 · 90% CI -0.09 to 0.04
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.956 · Mean difference (final values): 0.00 · 90% CI -0.06 to 0.06
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.403 · Mean difference (final values): -0.03 · 90% CI -0.10 to 0.03
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.617 · Mean difference (final values): 0.02 · 90% CI -0.04 to 0.08
SecondaryThe Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of Very Low Density Lipoprotein cholesterol by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Very Low Density Lipoprotein Cholesterol Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment-0.06 ± 0.37-0.01 ± 0.160.08 ± 0.19-0.02 ± 0.24-0.08 ± 0.31
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.815 · Mean difference (final values): 0.03 · 90% CI -0.16 to 0.21
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.418 · Mean difference (final values): 0.09 · 90% CI -0.09 to 0.26
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.236 · Mean difference (final values): 0.13 · 90% CI -0.05 to 0.32
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.556 · Mean difference (final values): 0.06 · 90% CI -0.11 to 0.23
SecondaryThe Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum triglyceride concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum Triglyceride Concentration After 91 Days (13 Weeks) of Treatment-0.47 ± 0.540.14 ± 0.280.09 ± 0.550.09 ± 0.66-0.12 ± 0.80
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.329 · Mean difference (final values): -0.24 · 90% CI -0.64 to 0.17
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.232 · Mean difference (final values): 0.28 · 90% CI -0.11 to 0.68
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.164 · Mean difference (final values): 0.31 · 90% CI -0.06 to 0.68
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.302 · Mean difference (final values): 0.24 · 90% CI -0.15 to 0.63
SecondaryThe Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of triglyceride concentrations by ultracentrifugation. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Triglyceride Concentration by Ultracentrifugation After 91 Days (13 Weeks) of Treatment-0.16 ± 0.560.12 ± 0.260.16 ± 0.340.05 ± 0.59-0.03 ± 0.74
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.614 · Mean difference (final values): -0.12 · 90% CI -0.50 to 0.27
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.669 · Mean difference (final values): 0.10 · 90% CI -0.28 to 0.48
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.621 · Mean difference (final values): 0.12 · 90% CI -0.28 to 0.52
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.867 · Mean difference (final values): 0.04 · 90% CI -0.33 to 0.41
SecondaryThe Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Apolipoprotein A. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · umol/l
The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment
umol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum Apolipoprotein A Concentration After 91 Days (13 Weeks) of Treatment-2.86 ± 8.84-3.51 ± 10.88-4.92 ± 6.040.64 ± 11.32-3.41 ± 6.22
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.335 · Mean difference (final values): 2.55 · 90% CI -1.84 to 6.95
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.358 · Mean difference (final values): 2.36 · 90% CI -1.90 to 6.62
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.900 · Mean difference (final values): 0.30 · 90% CI -3.72 to 4.33
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.019 · Mean difference (final values): 6.02 · 90% CI 1.86 to 10.19
SecondaryThe Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Apolipoprotein B. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · umol/l
The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment
umol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum Apolipoprotein B Concentration After 91 Days (13 Weeks) of Treatment-0.19 ± 0.840.18 ± 0.510.11 ± 0.530.08 ± 0.660.16 ± 0.42
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.325 · Mean difference (final values): -0.24 · 90% CI -0.65 to 0.17
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.438 · Mean difference (final values): 0.19 · 90% CI -0.21 to 0.59
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.701 · Mean difference (final values): 0.09 · 90% CI -0.29 to 0.47
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.624 · Mean difference (final values): -0.11 · 90% CI -0.50 to 0.27
SecondaryThe Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment

A decrease from baseline to the end of treatment (i.e. a negative value) in the Apolipoprotein B : Apolipoprotein A ratio indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · ratio
The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment
ratio1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum Apolipoprotein B : Apolipoprotein A Ratio After 91 Days (13 Weeks) of Treatment-0.01 ± 0.230.07 ± 0.150.08 ± 0.130.01 ± 0.140.07 ± 0.12
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.233 · Mean difference (final values): -0.07 · 90% CI -0.17 to 0.03
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.727 · Mean difference (final values): 0.02 · 90% CI -0.07 to 0.11
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.593 · Mean difference (final values): 0.03 · 90% CI -0.06 to 0.12
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.075 · Mean difference (final values): -0.10 · 90% CI -0.20 to -0.01
SecondaryThe Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of serum Non-Esterified Fatty Acid concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Serum Non-Esterified Fatty Acid Concentration After 91 Days (13 Weeks) of Treatment0.06 ± 0.17-0.03 ± 0.23-0.05 ± 0.30-0.02 ± 0.180.01 ± 0.15
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.236 · Mean difference (final values): 0.10 · 90% CI -0.04 to 0.24
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.579 · Mean difference (final values): 0.05 · 90% CI -0.09 to 0.18
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.837 · Mean difference (final values): -0.02 · 90% CI -0.15 to 0.11
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.467 · Mean difference (final values): 0.06 · 90% CI -0.08 to 0.19
SecondaryThe Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fasting glucose concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Fasting Glucose Concentration After 91 Days (13 Weeks) of Treatment-0.23 ± 2.020.44 ± 2.000.41 ± 0.82-0.76 ± 1.000.38 ± 1.15
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.533 · Mean difference (final values): -0.38 · 90% CI -1.41 to 0.64
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.804 · Mean difference (final values): 0.15 · 90% CI -0.84 to 1.13
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.916 · Mean difference (final values): 0.06 · 90% CI -0.87 to 0.99
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.040 · Mean difference (final values): -1.23 · 90% CI -2.20 to -0.25
SecondaryThe Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fructosamine concentrations. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · umol/l
The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment
umol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Fructosamine Concentration After 91 Days (13 Weeks) of Treatment2.8 ± 42.0614.5 ± 29.53-2.6 ± 20.411.1 ± 11.689.5 ± 19.68
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.366 · Mean difference (final values): -9.90 · 90% CI -28.06 to 8.27
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.844 · Mean difference (final values): 2.11 · 90% CI -15.81 to 20.03
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.118 · Mean difference (final values): -15.96 · 90% CI -32.76 to 0.84
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.518 · Mean difference (final values): -6.67 · 90% CI -23.86 to 10.51
SecondaryThe Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of glycated haemoglobin concentrations. At both time points, values were calculated as a percentage of total haemoglobin. A decrease from baseline to the end of treatment in base per cent values, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · percent
The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment
percent1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Glycated Haemoglobin Concentration After 91 Days (13 Weeks) of Treatment0.14 ± 1.410.16 ± 0.440.08 ± 0.44-0.03 ± 0.220.31 ± 0.54
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.576 · Mean difference (final values): -0.17 · 90% CI -0.66 to 0.33
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.648 · Mean difference (final values): -0.13 · 90% CI -0.60 to 0.34
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.447 · Mean difference (final values): -0.21 · 90% CI -0.66 to 0.24
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.273 · Mean difference (final values): -0.31 · 90% CI -0.79 to 0.16
SecondaryThe Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])

A two-hour OGTT was performed to investigate the rate of glucose metabolism or clearance from the blood with treatment. Blood samples were taken at -15 and 0 minutes prior to a glucose drink and at 30, 60, 90, 120 and 180 minutes post drink. The OGTT measured the change from baseline in serum glucose levels at two hours (120 minutes) compared to 0 minutes. The extent of the elevation in blood glucose levels following a glucose drink were compared between baseline and the end of treatment. A reduction in the elevation of serum glucose levels at the end of treatment (i.e. a negative value) indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · mmol/l
The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])
mmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Glucose Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test [OGTT])-0.07 ± 1.891.09 ± 3.81-0.78 ± 1.510.22 ± 1.850.42 ± 1.44
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.615 · Mean difference (final values): -0.56 · 90% CI -2.40 to 1.29
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.342 · Mean difference (final values): 0.93 · 90% CI -0.70 to 2.57
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.314 · Mean difference (final values): -0.95 · 90% CI -2.52 to 0.62
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.889 · Mean difference (final values): 0.14 · 90% CI -1.48 to 1.75
SecondaryThe Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)

At baseline and the end of treatment, blood samples were taken at -15 and 0 minutes prior to a glucose drink and at 30, 60, 90, 120 and 180 minutes post drink. The OGTT measured the change from baseline in serum insulin levels at two hours (120 minutes) compared to 0 minutes. The extent of the elevation in blood glucose levels following a glucose drink were compared between baseline and the end of treatment. An increase in the elevation of serum insulin levels from baseline to the end of treatment (i.e. a positive value) indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · pmol/l
The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)
pmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline to the End of 91 Days (13 Weeks) of Treatment in the Mean Serum Insulin Concentration Two Hours Post Glucose Challenge (Oral Glucose Tolerance Test)80.9 ± 223.91-156.6 ± 358.53-193.5 ± 232.1783.5 ± 427.94-40.8 ± 475.88
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.764 · Mean difference (final values): 50.89 · 90% CI -232.02 to 333.80
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.654 · Mean difference (final values): -70.76 · 90% CI -333.96 to 192.44
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.450 · Mean difference (final values): -111.50 · 90% CI -357.17 to 134.16
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.517 · Mean difference (final values): 97.42 · 90% CI -153.02 to 347.86
SecondaryThe Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of fasting insulin concentrations. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · pmol/l
The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment
pmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Fasting Insulin Concentration After 91 Days (13 Weeks) of Treatment12.01 ± 56.22-6.06 ± 104.7813.44 ± 49.0345.62 ± 183.922.79 ± 61.44
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.840 · Mean difference (final values): 8.33 · 90% CI -60.28 to 76.94
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.834 · Mean difference (final values): 8.31 · 90% CI -57.92 to 74.55
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.767 · Mean difference (final values): -11.62 · 90% CI -77.06 to 53.81
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.289 · Mean difference (final values): 42.51 · 90% CI -23.99 to 109.01
SecondaryThe Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment

At baseline and the end of treatment, an approximately 30 mL fasting blood sample was taken for measurement of C-peptide concentrations. An increase from baseline to the end of treatment, a positive value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · nmol/l
The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment
nmol/l1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean C-peptide Concentration After 91 Days (13 Weeks) of Treatment0.02 ± 0.150.09 ± 0.28-0.03 ± 0.180.12 ± 0.310.09 ± 0.25
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.569 · Mean difference (final values): -0.06 · 90% CI -0.24 to 0.12
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.984 · Mean difference (final values): 0.00 · 90% CI -0.17 to 0.17
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.176 · Mean difference (final values): -0.13 · 90% CI -0.30 to 0.03
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.895 · Mean difference (final values): 0.01 · 90% CI -0.15 to 0.18
SecondaryThe Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment

Changes from baseline to the end of treatment in mean insulin resistance were calculated by HOMA2-IR. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin resistance, which is the reciprocal of insulin sensitivity (%S)(100/%S) as a percentage of a normal reference population (normal young adults). A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · IR score
The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment
IR score1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Insulin Resistance Measured by Homeostasis Model Assessment 2 (HOMA2-IR) After 91 Days (13 Weeks) of Treatment0.19 ± 1.00-0.19 ± 2.540.35 ± 1.200.64 ± 3.150.09 ± 1.22
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.871 · Mean difference (final values): 0.12 · 90% CI -1.13 to 1.37
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.826 · Mean difference (final values): 0.16 · 90% CI -1.05 to 1.37
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.693 · Mean difference (final values): -0.28 · 90% CI -1.46 to 0.90
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.536 · Mean difference (final values): 0.45 · 90% CI -0.76 to 1.66
SecondaryThe Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment

Changes from baseline to the end of treatment in mean insulin sensitivity were calculated by HOMA2. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). An increase from baseline to the end of treatment, a positive value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · percent sensitivity
The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment
percent sensitivity1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Insulin Sensitivity Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment-5.26 ± 8.62-1.71 ± 12.621.71 ± 26.486.47 ± 27.00-4.07 ± 13.16
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.878 · Mean difference (final values): -1.33 · 90% CI -15.80 to 13.13
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.919 · Mean difference (final values): 0.85 · 90% CI -13.18 to 14.89
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.557 · Mean difference (final values): 4.72 · 90% CI -8.67 to 18.11
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.275 · Mean difference (final values): 9.20 · 90% CI -4.76 to 23.16
SecondaryThe Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment

Changes from baseline to the end of treatment in mean insulin B Cell Function were calculated by HOMA2. HOMA2-IR is a computer model that uses fasting plasma insulin and glucose concentrations to estimate beta cell function (%B) as a percentage of a normal reference population (normal young adults). An increase from baseline to the end of treatment, a positive value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · percent beta function
The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment
percent beta function1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Insulin B Cell Function Measured by Homeostasis Model Assessment 2 (HOMA2) After 91 Days (13 Weeks) of Treatment8.13 ± 23.56-7.64 ± 35.00-1.31 ± 19.0636.59 ± 70.55-2.41 ± 19.96
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.528 · Mean difference (final values): 10.45 · 90% CI -17.12 to 38.01
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.990 · Mean difference (final values): 0.20 · 90% CI -26.32 to 26.72
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.776 · Mean difference (final values): 4.39 · 90% CI -21.37 to 30.15
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.007 · Mean difference (final values): 44.51 · 90% CI 17.98 to 71.05
SecondaryThe Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment

Body Mass Index was calculated at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · kg/m^2
The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment
kg/m^21:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Body Mass Index After 91 Days (13 Weeks) of Treatment-0.38 ± 0.65-0.02 ± 0.72-0.20 ± 1.16-0.21 ± 1.09-0.50 ± 2.12
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.717 · Mean difference (final values): 0.20 · 90% CI -0.70 to 1.09
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.218 · Mean difference (final values): 0.66 · 90% CI -0.23 to 1.55
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.378 · Mean difference (final values): 0.46 · 90% CI -0.40 to 1.32
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.361 · Mean difference (final values): 0.49 · 90% CI -0.40 to 1.38
SecondaryThe Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment

Subject's waist-to-hip ratios were calculated at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · ratio
The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment
ratio1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Waist-to-hip Ratio After 91 Days (13 Weeks) of Treatment-0.00 ± 0.06-0.00 ± 0.040.00 ± 0.03-0.00 ± 0.02-0.01 ± 0.02
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.417 · Mean difference (final values): 0.01 · 90% CI -0.01 to 0.03
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.340 · Mean difference (final values): 0.01 · 90% CI -0.01 to 0.04
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.915 · Mean difference (final values): -0.00 · 90% CI -0.02 to 0.02
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.465 · Mean difference (final values): 0.01 · 90% CI -0.01 to 0.03
SecondaryThe Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment

Subject's body weights were measured at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · kg
The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment
kg1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Body Weight After 91 Days (13 Weeks) of Treatment-1.05 ± 1.88-0.10 ± 2.07-0.46 ± 3.40-0.66 ± 3.09-1.64 ± 6.66
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.646 · Mean difference (final values): 0.75 · 90% CI -1.96 to 3.45
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.219 · Mean difference (final values): 1.99 · 90% CI -0.69 to 4.66
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.307 · Mean difference (final values): 1.61 · 90% CI -1.00 to 4.23
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.348 · Mean difference (final values): 1.52 · 90% CI -1.17 to 4.22
SecondaryThe Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment

Subjects' waist measurements were taken at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · cm
The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment
cm1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Waist Measurement After 91 Days (13 Weeks) of Treatment0.82 ± 3.90-0.17 ± 2.590.31 ± 4.31-0.39 ± 1.48-0.86 ± 2.55
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.187 · Mean difference (final values): 1.74 · 90% CI -0.44 to 3.91
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.578 · Mean difference (final values): 0.72 · 90% CI -1.43 to 2.86
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.368 · Mean difference (final values): 1.13 · 90% CI -0.96 to 3.22
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.696 · Mean difference (final values): 0.51 · 90% CI -1.67 to 2.69
SecondaryThe Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment

Subjects' hip measurements were taken at baseline and the end of treatment. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · cm
The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment
cm1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Hip Measurement After 91 Days (13 Weeks) of Treatment1.12 ± 4.930.07 ± 2.540.38 ± 3.48-0.19 ± 1.30-0.20 ± 2.86
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.327 · Mean difference (final values): 1.30 · 90% CI -0.90 to 3.51
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.851 · Mean difference (final values): 0.25 · 90% CI -1.93 to 2.43
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.672 · Mean difference (final values): 0.54 · 90% CI -1.60 to 2.69
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.978 · Mean difference (final values): -0.04 · 90% CI -2.26 to 2.18
SecondaryThe Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment

Visceral Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Visceral Abdominal Fat After 91 Days (13 Weeks) of Treatment0.10 ± 0.960.62 ± 1.020.42 ± 0.87-0.11 ± 0.780.27 ± 1.97
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.857 · Mean difference (final values): -0.09 · 90% CI -0.95 to 0.76
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.543 · Mean difference (final values): 0.34 · 90% CI -0.58 to 1.26
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.859 · Mean difference (final values): 0.09 · 90% CI -0.74 to 0.92
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.467 · Mean difference (final values): -0.39 · 90% CI -1.27 to 0.50
SecondaryThe Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment

Subcutaneous Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Subcutaneous Abdominal Fat After 91 Days (13 Weeks) of Treatment-0.3 ± 1.050.5 ± 0.56-0.0 ± 0.660.1 ± 0.840.3 ± 1.39
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.124 · Mean difference (final values): -0.64 · 90% CI -1.32 to 0.05
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.909 · Mean difference (final values): 0.05 · 90% CI -0.68 to 0.79
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.245 · Mean difference (final values): -0.46 · 90% CI -1.12 to 0.20
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.382 · Mean difference (final values): -0.36 · 90% CI -1.05 to 0.33
SecondaryThe Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment

Total Abdominal Fat was measured by magnetic resonance imaging, and the results of the scans were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Total Abdominal Fat After 91 Days (13 Weeks) of Treatment-0.23 ± 1.531.08 ± 1.420.37 ± 1.25-0.05 ± 1.520.59 ± 3.24
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.376 · Mean difference (final values): -0.75 · 90% CI -2.15 to 0.66
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.688 · Mean difference (final values): 0.37 · 90% CI -1.15 to 1.89
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.637 · Mean difference (final values): -0.38 · 90% CI -1.73 to 0.96
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.355 · Mean difference (final values): -0.79 · 90% CI -2.22 to 0.63
SecondaryThe Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

Internal Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Internal Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment-0.22 ± 1.13-0.75 ± 0.870.02 ± 0.62-0.29 ± 0.75-0.37 ± 0.43
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.482 · Mean difference (final values): 0.28 · 90% CI -0.39 to 0.95
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.708 · Mean difference (final values): 0.19 · 90% CI -0.65 to 1.02
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.166 · Mean difference (final values): 0.62 · 90% CI -0.12 to 1.37
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.424 · Mean difference (final values): 0.33 · 90% CI -0.37 to 1.03
SecondaryThe Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

Subcutaneous Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Subcutaneous Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment0.6 ± 2.980.4 ± 1.350.2 ± 1.370.8 ± 3.17-2.4 ± 2.45
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.022 · Mean difference (final values): 3.10 · 90% CI 0.94 to 5.25
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.014 · Mean difference (final values): 4.07 · 90% CI 1.44 to 6.69
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.053 · Mean difference (final values): 2.85 · 90% CI 0.45 to 5.25
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.012 · Mean difference (final values): 3.56 · 90% CI 1.33 to 5.78
SecondaryThe Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment

Total Non-Abdominal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Total Non-Abdominal Fat After 91 Days (13 Weeks) of Treatment0.33 ± 3.81-0.36 ± 1.520.18 ± 1.990.56 ± 3.87-2.81 ± 2.37
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.032 · Mean difference (final values): 3.35 · 90% CI 0.84 to 5.85
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.026 · Mean difference (final values): 4.27 · 90% CI 1.18 to 7.35
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.046 · Mean difference (final values): 3.44 · 90% CI 0.65 to 6.22
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.018 · Mean difference (final values): 3.86 · 90% CI 1.26 to 6.45
SecondaryThe Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment

Total Internal Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Total Internal Fat After 91 Days (13 Weeks) of Treatment-0.09 ± 2.130.46 ± 0.560.40 ± 1.07-0.52 ± 1.29-0.88 ± 1.36
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.294 · Mean difference (final values): 0.87 · 90% CI -0.52 to 2.25
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.092 · Mean difference (final values): 1.74 · 90% CI 0.05 to 3.43
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.173 · Mean difference (final values): 1.26 · 90% CI -0.28 to 2.79
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.545 · Mean difference (final values): 0.51 · 90% CI -0.92 to 1.95
SecondaryThe Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment

Total Subcutaneous Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Total Subcutaneous Fat After 91 Days (13 Weeks) of Treatment0.22 ± 2.631.11 ± 0.780.01 ± 1.881.08 ± 3.26-2.44 ± 2.25
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.038 · Mean difference (final values): 2.67 · 90% CI 0.59 to 4.75
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.004 · Mean difference (final values): 4.71 · 90% CI 2.16 to 7.26
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.088 · Mean difference (final values): 2.40 · 90% CI 0.09 to 4.72
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.010 · Mean difference (final values): 3.54 · 90% CI 1.39 to 5.68
SecondaryThe Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment

Total Fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Total Fat After 91 Days (13 Weeks) of Treatment0.13 ± 4.611.57 ± 0.460.40 ± 2.650.57 ± 4.34-3.31 ± 2.91
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.064 · Mean difference (final values): 3.53 · 90% CI 0.42 to 6.64
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.008 · Mean difference (final values): 6.55 · 90% CI 2.72 to 10.38
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.084 · Mean difference (final values): 3.65 · 90% CI 0.19 to 7.10
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.041 · Mean difference (final values): 4.05 · 90% CI 0.84 to 7.25
SecondaryThe Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment

Abdominal Adiposity was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · litres
The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment
litres1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Abdominal Adiposity After 91 Days (13 Weeks) of Treatment-0.02 ± 0.080.05 ± 0.06-0.01 ± 0.060.01 ± 0.080.04 ± 0.10
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.129 · Mean difference (net): -0.07 · 90% CI -0.14 to 0.01
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.961 · Mean difference (final values): 0.00 · 90% CI -0.08 to 0.09
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.128 · Mean difference (final values): -0.08 · 90% CI -0.16 to 0.01
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.300 · Mean difference (final values): -0.05 · 90% CI -0.12 to 0.03
SecondaryThe Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment

Percentage liver fat was measured by magnetic resonance imaging at baseline and the end of treatment, and the results of the scan were analysed blind by a single independent reviewer. A decrease from baseline to the end of treatment in base per cent values, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · percent liver fat
The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment
percent liver fat1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean % Liver Fat After 91 Days (13 Weeks) of Treatment-1.12 ± 19.750.37 ± 7.15-4.73 ± 9.870.77 ± 10.56-2.95 ± 12.40
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.625 · Mean difference (final values): 2.65 · 90% CI -6.37 to 11.67
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.226 · Mean difference (final values): 6.77 · 90% CI -2.48 to 16.02
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.904 · Mean difference (final values): 0.62 · 90% CI -7.94 to 9.18
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.285 · Mean difference (final values): 6.17 · 90% CI -3.41 to 15.75
SecondaryThe Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment

Subjects scored their appetite daily using an appetite 0-10 numerical rating scale score where 0 = no appetite (don't feel hungry) and 10 = maximum appetite (completely hungry all the time). The mean change from baseline to the end of treatment in scores were calculated. A decrease from baseline to the end of treatment, a negative value, indicates an improvement.

Time frame:
Baseline (Day 1) and End of treatment (Day 92)
Reported as:
Mean · units on a scale
The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment
units on a scale1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Appetite 0-10 Numerical Rating Scale Score After 91 Days (13 Weeks) of Treatment-1.19 ± 2.02-0.84 ± 1.96-0.69 ± 0.99-0.36 ± 2.01-0.59 ± 1.10
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.138 · Mean difference (final values): -0.85 · 90% CI -1.81 to 0.10
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.505 · Mean difference (final values): -0.37 · 90% CI -1.28 to 0.55
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.743 · Mean difference (final values): 0.18 · 90% CI -0.73 to 1.08
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.540 · Mean difference (final values): 0.35 · 90% CI -0.60 to 1.29
SecondaryAdverse Events as a Measure of Patient Safety

The incidence of treatment-emergent adverse events was recorded for the study duration, and the number of patients who experienced an adverse event is presented.

Time frame:
Day 1 - Day 92
Reported as:
Number · participants
Adverse Events as a Measure of Patient Safety
participants1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
Adverse Events as a Measure of Patient Safety78111113
SecondaryThe Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment

The BDI-II is a 21 question, multiple choice, self-reported inventory, and is one of the most widely used instruments for measuring the severity of depression. The 21 questions or items each had four possible responses. Each response was assigned a score ranging from zero to three, indicating the severity of the symptom, with a total possible score ranging from zero to 63. A score between zero and 13 indicates 'minimal depression'. A score between 14 and 19 indicates 'mild depression'. A score between 20 and 28 indicates 'moderate depression', and a score between 29 and 63 indicates 'severe depression'. As such, an increase from baseline to the end of treatment, a positive value, indicates a deterioration.

Time frame:
Baseline (Day 1) and the End of Treatment (Day 92)
Reported as:
Mean · units on a scale
The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment
units on a scale1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
The Change From Baseline in Mean Beck Depression Inventory-II (BDI-II) Score at the End of 91 Days (13 Weeks) of Treatment0.27 ± 1.274.91 ± 8.080.85 ± 2.230.58 ± 2.15-0.08 ± 4.17
Statistical analysis
  • 1:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.701 · Mean difference (final values): 0.64 · 90% CI -2.14 to 3.43
  • 20:1 GWP42003 : GWP42004 vs Placebo · ANCOVA · p = 0.006 · Mean difference (final values): 4.77 · 90% CI 1.99 to 7.55
  • GWP42003 and Placebo vs Placebo · ANCOVA · p = 0.542 · Mean difference (final values): 0.98 · 90% CI -1.68 to 3.64
  • GWP42004 and Placebo vs Placebo · ANCOVA · p = 0.827 · Mean difference (final values): 0.36 · 90% CI -2.36 to 3.08

Adverse events

Collected over All adverse events occurring during the study (up to 133 days) were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1:1 GWP42003 : GWP42004—1/11 (9.1%)7/11 (63.6%)
20:1 GWP42003 : GWP42004—2/12 (16.7%)8/12 (66.7%)
GWP42003 and Placebo—0/13 (0%)11/13 (84.6%)
GWP42004 and Placebo—0/12 (0%)11/12 (91.7%)
Placebo—1/14 (7.1%)13/14 (92.9%)
Most frequent serious events
Most frequent serious events
Event1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
Self-injurious ideationPsychiatric disorders1/110/120/130/120/14
Myocardial infarctionCardiac disorders0/111/120/130/120/14
Suicidal ideationPsychiatric disorders0/111/120/130/120/14
Myocardial ischaemiaCardiac disorders0/110/120/130/121/14
Most frequent other events
Showing 10 of 75
Most frequent other events
Event1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlacebo
Decreased appetiteMetabolism and nutrition disorders1/110/122/134/122/14
DiarrhoeaGastrointestinal disorders0/110/121/132/120/14
NasopharyngitisInfections and infestations1/111/121/132/120/14
ArthralgiaMusculoskeletal and connective tissue disorders0/112/121/130/120/14
HaematuriaRenal and urinary disorders0/110/120/132/122/14
InfluenzaInfections and infestations0/111/121/131/122/14
Musculoskeletal painMusculoskeletal and connective tissue disorders0/110/120/130/122/14
DizzinessNervous system disorders1/110/120/131/122/14
FlatulenceGastrointestinal disorders1/110/121/130/120/14
FatigueGeneral disorders1/111/120/131/121/14

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlaceboTotal
<=18 years000000
Between 18 and 65 years8111181048
>=65 years3124414
Age, Continuous
Age, Continuous(years)1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlaceboTotal
Mean59.33 ± 8.7557.96 ± 8.1156.80 ± 9.9262.45 ± 12.5858.63 ± 7.7258.98 ± 9.41
Sex: Female, Male
Sex: Female, Male(Participants)1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlaceboTotal
Female5332720
Male691010742
Region of Enrollment
Region of Enrollment(participants)1:1 GWP42003 : GWP4200420:1 GWP42003 : GWP42004GWP42003 and PlaceboGWP42004 and PlaceboPlaceboTotal
United Kingdom111213121462
08

Study locations

5 sites
  • Woolpit Health Centre
    Bury Saint Edmonds, IP30 9QU, United Kingdom
  • Mount Farm Surgery
    Bury Saint Edmonds, IP32 7EW, United Kingdom
  • University of Nottingham, Medical School at Derby, Royal Derby Hospital
    Derby, DE22 3DT, United Kingdom
  • James Paget University Hospital
    Gorleston-on-Sea, Norfolk, NR31 6LA, United Kingdom
  • MAC UK Neuroscience Ltd.
    Manchester, M32 0UT, United Kingdom
09

References and documents

Publications

  • Jadoon KA, Ratcliffe SH, Barrett DA, Thomas EL, Stott C, Bell JD, O'Sullivan SE, Tan GD. Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care. 2016 Oct;39(10):1777-86. doi: 10.2337/dc16-0650. Epub 2016 Aug 29. PubMed 27573936 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of May 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2010
First posted
Oct 8, 2010
Start
Oct 2010
Primary completionActual
May 2012
CompletionActual
Sep 2012
Results first posted
Jan 20, 2014
Last update
Oct 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01217112
Responsible party
Sponsor
First posted
Oct 8, 2010
Start date
Oct 2010
Primary completion
May 2012
Completion
Sep 2012
Results posted
Jan 20, 2014
Last update
Oct 18, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cannabidiol · Tetrahydrocannabivarin

Start the discussion